Cellular therapies company Actinium Pharmaceuticals Inc (NYSE American:ATNM) reported on Tuesday the election of Mamata Gokhale, PhD, RAC as vice president, global head of its Regulatory Affairs.
In the senior position, Dr Gokhale will develop and implement a comprehensive clinical regulatory strategy across the company's portfolio of ARC or Antibody Radiation-Conjugate product candidates for targeted conditioning, including] the pivotal Phase 3 trial for its lead candidate Iomab-B, therapeutic and combination trials of Actimab-A, as well as potential next-generation ARC's resulting from its AWE or Antibody Warhead Enabling technology platform.
Previously, Dr Gokhale has worked at biotechnology and pharma companies including Amgen, Watson Pharma, Neumedicines Inc as well as in global Contract Research Organisations including Voisin Consulting Life Sciences and Paraxel International.
Earlier in her career, Dr Gokhale was part of the US Food and Drug Administration for over 20 years in regulatory positions of increasing responsibility.
Sengenics Partners with the Foundation for the National Institutes of Health Biomarkers Consortium
Noven Names Purcell as Head of Marketing and Sales
US FDA receives Biologics License Application from Janssen Pharmaceutical for DARZALEX
Schrödinger announces research based milestone payment from Ono
AstraZeneca announces grant by US FDA of Orphan Drug Designation to Imfinzi